Literature DB >> 27551008

Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient.

Maria F Mojica1, Christopher P Ouellette2, Amy Leber3, M Brian Becknell4, Monica I Ardura2, Federico Perez5, Masako Shimamura6, Robert A Bonomo7, Samuel L Aitken8, Samuel A Shelburne9.   

Abstract

Stenotrophomonas maltophilia is an emerging multidrug-resistant (MDR) opportunistic pathogen for which new antibiotic options are urgently needed. We report our clinical experience treating a 19-year-old renal transplant recipient who developed prolonged bacteremia due to metallo-β-lactamase-producing S. maltophilia refractory to conventional treatment. The infection recurred despite a prolonged course of colistimethate sodium (colistin) but resolved with the use of a novel drug combination with clinical efficacy against the patient's S. maltophilia isolate.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27551008      PMCID： PMC4997835          DOI： 10.1128/AAC.00264-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.

Authors:  Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

2.  In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.

Authors:  Douglas J Biedenbach; Krystyna Kazmierczak; Samuel K Bouchillon; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

Review 3.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

Review 4.  Combination therapy for treatment of infections with gram-negative bacteria.

Authors:  Pranita D Tamma; Sara E Cosgrove; Lisa L Maragakis
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

Review 5.  Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature.

Authors:  Matthew E Falagas; Antonia C Kastoris; Evridiki K Vouloumanou; Petros I Rafailidis; Anastasios M Kapaskelis; George Dimopoulos
Journal:  Future Microbiol       Date:  2009-11       Impact factor: 3.165

Review 6.  Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems.

Authors:  Oren Zusman; Tomer Avni; Leonard Leibovici; Amos Adler; Lena Friberg; Theodouli Stergiopoulou; Yehuda Carmeli; Mical Paul
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

7.  Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples.

Authors:  M Denton; N J Todd; K G Kerr; P M Hawkey; J M Littlewood
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

8.  Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Krystyna M Kazmierczak; Sharon Rabine; Meredith Hackel; Robert E McLaughlin; Douglas J Biedenbach; Samuel K Bouchillon; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

9.  High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.

Authors:  Samuel L Aitken; Jeffrey J Tarrand; Lalitagauri M Deshpande; Frank P Tverdek; Anne L Jones; Samuel A Shelburne; Randall A Prince; Micah M Bhatti; Kenneth V I Rolston; Ronald N Jones; Mariana Castanheira; Roy F Chemaly
Journal:  Clin Infect Dis       Date:  2016-06-16       Impact factor: 9.079

Review 10.  Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.

Authors:  Ya-Ting Chang; Chun-Yu Lin; Yen-Hsu Chen; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2015-09-02       Impact factor: 5.640
View more
  21 in total

Review 1.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

2.  Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug-Resistant Klebsiella pneumoniae in a Multivisceral Transplant Patient.

Authors:  Rossana Rosa; Susan D Rudin; Laura J Rojas; Armando Perez-Cardona; Laura Aragon; David P Nicolau; Federico Perez; Andrea M Hujer; Akin Tekin; Octavio Martinez; Jose F Camargo; Robert A Bonomo; Lilian M Abbo
Journal:  Clin Infect Dis       Date:  2017-08-15       Impact factor: 9.079

3.  Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.

Authors:  Maria F Mojica; Krisztina M Papp-Wallace; Magdalena A Taracila; Melissa D Barnes; Joseph D Rutter; Michael R Jacobs; John J LiPuma; Thomas J Walsh; Alejandro J Vila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

4.  [New antibiotics for severe infections due to multidrug-resistant pathogens : Definitive treatment and escalation].

Authors:  D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

Review 5.  Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor Combinations.

Authors:  Stephanie Ho; Lynn Nguyen; Trang Trinh; Conan MacDougall
Journal:  Curr Infect Dis Rep       Date:  2019-09-09       Impact factor: 3.725

6.  Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.

Authors:  Mohamad Yasmin; Derrick E Fouts; Michael R Jacobs; Hanan Haydar; Steven H Marshall; Richard White; Roshan D'Souza; Thomas P Lodise; Daniel D Rhoads; Andrea M Hujer; Laura J Rojas; Claudia Hoyen; Federico Perez; Amy Edwards; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

Review 7.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

8.  Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?

Authors:  Steven Marshall; Andrea M Hujer; Laura J Rojas; Krisztina M Papp-Wallace; Romney M Humphries; Brad Spellberg; Kristine M Hujer; Emma K Marshall; Susan D Rudin; Federico Perez; Brigid M Wilson; Ronald B Wasserman; Linda Chikowski; David L Paterson; Alejandro J Vila; David van Duin; Barry N Kreiswirth; Henry F Chambers; Vance G Fowler; Michael R Jacobs; Mark E Pulse; William J Weiss; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

9.  Transplant tourism complicated by life-threatening New Delhi metallo-β-lactamase-1 infection.

Authors:  Jenell Stewart; Gretchen Snoeyenbos Newman; Rupali Jain; Andrew Bryan; Heather Berger; Martin Montenovo; Ramasamy Bakthavatsalam; Catherine E Kling; Lena Sibulesky; Sherene Shalhub; Ajit P Limaye; Cynthia E Fisher; Robert M Rakita
Journal:  Am J Transplant       Date:  2018-10-29       Impact factor: 8.086

10.  Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.

Authors:  M Biagi; D Lamm; K Meyer; A Vialichka; M Jurkovic; S Patel; R E Mendes; Z P Bulman; E Wenzler
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.